Ajanta Pharma Limited has informed the Exchange regarding Board meeting held on November 03, 2025.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma reported Q2 FY26 consolidated revenue of Rs. 1,354 crore, up 14% year-on-year, with profit after tax of Rs. 260 crore, up 20% YoY. EBITDA was Rs. 328 crore at a 24% margin; excluding a Rs. 41 crore mark-to-market forex loss, EBITDA margin stood at a healthier 27%. For the first half of FY26, revenue grew 14% to Rs. 2,656 crore and PAT grew 12% to Rs. 516 crore, with ROCE at 30% and RONW at 25%. US generics was the standout segment, growing 48% YoY in Q2, while India branded generics grew 12%. The board declared a 1st interim dividend of Rs. 28 per share (on face value of Rs. 2), totaling Rs. 349.82 crore, with record date November 10, 2025 and payment from November 20, 2025. Auditors B S R & Co. LLP issued an unmodified review opinion.
Strong earnings growth driven mainly by US generics and India branded businesses, combined with a generous interim dividend, should be positive for shareholders. Investors should note the disclosed Income Tax search in August 2025, though no financial impact has been quantified yet and auditors have given a clean opinion.